Next-Generation CAR-T and CAR-NK Cell Therapies Show Promise in Cancer Treatment
Recent advances in chimeric antigen receptor cell therapies highlight improved designs for CAR-T and CAR-NK treatments, with new strategies addressing efficacy and safety challenges in both hematologic and solid tumors.
A new editorial perspective published in Volume 17 of Oncotarget on February 20, 2026, reviews recent clinical and translational advances in chimeric antigen receptor T-cell (CAR-T) therapy and highlights both its promise and its remaining barriers. The perspective synthesizes recent clinical advances in hematologic malignancies and emerging applications in solid tumors, while focusing attention on safety (for example, cytokine release syndrome and neurotoxicity), resistance, antigen specificity, and access disparities.
The editorial summarizes the CAR-T workflow (leukapheresis → genetic modification and expansion → infusion) and notes major recent clinical gains — including improved outcomes in leukemia, lymphoma, and multiple myeloma — that support wider adoption of cellular immunotherapy approaches. Despite these advances, important clinical challenges remain, particularly for solid tumors, where antigen selection, tumor microenvironment, and T-cell trafficking limit efficacy.
The authors call out clear next steps for the field: (1) continued refinement of CAR constructs (dual-targeting, switchable/on-off systems, armored CARs) to improve specificity and reduce on-target/off-tumor toxicity; (2) improved management protocols and prophylactic measures to mitigate CRS and neurotoxicity; (3) expanded investigation of allogeneic or alternative CAR-T platforms to address manufacturing, cost, and access barriers; and (4) focused translational studies to improve T-cell trafficking and efficacy in solid tumors. They also highlight equity issues — socioeconomic and racial disparities that limit access to CAR-T — and urge that broad deployment plans include strategies to expand availability and affordability.
In parallel research on CAR-NK therapies, researchers at the Ribeirão Preto Blood Center and the Center for Cell-Based Therapy conducted a study using the NK-92 cell line to test new models of chimeric antigen receptors with specific costimulatory domains, such as 2B4 and DAP12. The tests showed that these components helped make the cells "ready to attack," thereby increasing their ability to destroy tumors. The results were published in the journal Frontiers in Immunology.
CAR-based cell therapies are revolutionizing cancer treatment, especially for hematological tumors. However, although it is already known which components work best in CAR-T cells, many questions remain about which intracellular signals make CAR-NK cells more effective.
The research demonstrates that combining optimized co-stimulation with reversible pharmacological control can enhance the potency and efficiency of CAR-NK therapies, paving the way for new generations of cell therapies. The research also evaluated using the drug dasatinib temporarily to control the activation of these cells. In animal models, CAR-NK cells with 2B4-DAP12, pretreated with dasatinib, showed better tumor control compared to traditional versions.